Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Research Institute of Blood Lipid and Atherosclerosis, Central South University, Changsha, China.
J Transl Med. 2022 Mar 22;20(1):141. doi: 10.1186/s12967-021-03220-7.
Sufficient epidemiological investigations demonstrate that there is a close correlation between obesity and vascular dysfunction. Nevertheless, specific mechanisms underlying this link remain currently unclear. Given the crucial and decisive role of vascular dysfunction in multitudinous diseases, various hypotheses had been proposed and numerous experiments were being carried out. One recognized view is that increased adipokine secretion following the expanded mass of white adipose tissue due to obesity contributes to the regulation of vascular function. Chemerin, as a neo-adipokine, whose systemic level is elevated in obesity, is believed as a regulator of adipogenesis, inflammation, and vascular dysfunction via binding its cell surface receptor, chemR23. Hence, this review aims to focus on the up-to-date proof on chemerin/chemR23 axis-relevant signaling pathways, emphasize the multifarious impacts of chemerin/chemR23 axis on vascular function regulation, raise certain unsettled questions to inspire further investigations, and explore the therapeutic possibilities targeting chemerin/chemR23.
充分的流行病学调查表明，肥胖与血管功能障碍密切相关。然而，目前尚不清楚这种联系的具体机制。鉴于血管功能障碍在多种疾病中的关键和决定性作用，已经提出了各种假设，并进行了大量实验。一种公认的观点是，肥胖导致白色脂肪组织体积增大，随之增加的脂肪因子分泌有助于调节血管功能。趋化素作为一种新的脂肪因子，其在肥胖症中的系统水平升高，被认为通过与其细胞表面受体 chemR23 结合，调节脂肪生成、炎症和血管功能障碍。因此，本综述旨在关注趋化素/chemR23 轴相关信号通路的最新证据，强调趋化素/chemR23 轴对血管功能调节的多方面影响，提出一些未解决的问题以激发进一步的研究，并探讨针对趋化素/chemR23 的治疗可能性。
Zotero 插件
